6.7-Difluoroquinoxaline (I) reacted with dimedone, indandione, and 3-methyl-1-phenylpyrazol-5-one in DMSO solution in the presence of acid to form mono-substituted products IIa -c. Heating I with resorcinol in EtOH in the presence of acid gave resorcinol derivative IId. 6.7-Difluoroquinoxaline in the presence of base reacted with 3-methyl-1-phenylmethylpyrazol-5-one to form dipyrazolylmethane III and tetrapyrazolylethane derivative IV. Heating products IIa -c with N-methylpiperazine produced 7-methylpiperazine derivatives Va -c of 2-substituted quinoxalines.
Compounds with various types of biological activity have been found among quinoxaline derivatives [1, 2] . The quinoxaline derivatives quinoxidine and dioxidine have been used as antimicrobial agents [3] . A series of condensed quinoxalines were patented as anticancer drugs [4] .
Substituted quinoxalines are synthesized either by condensation of the corresponding substituted o-phenylenediamines with 1.2-dioxo-derivatives or via substitution reactions of easily displaced functional groups in the quinoxaline core. Substitution reactions of F atoms in 6.7-difluoroquinoxalines with various nucleophiles were reported [5] . We recently described substitution reactions of hydrogen in the heterocyclic core of unsubstituted quinoxaline by several C-nucleophiles [6] .
Herein we found that 6.7-difluoroquinoxaline (I) reacted with CH-acids such as dimedone, indandione, and 3-methyl-1-phenylmethylpyrazol-5-one in DMSO solution at room temperature in the presence of acid to form mono-substituted products IIa -c (Scheme 1).
Heating I with resorcinol in refluxing EtOH in the presence of HCl produced 4-(6.7-difluoroquinoxalin-2-yl)benzene-1.3-diol (IId).
The molecular weights of compounds II as determined by mass spectrometry agreed with the calculated values. A characteristic diagnostic signature in the PMR spectrum of mono-substituted products II was the presence of a separate resonance for the proton of the pyrazine ring at 9.0 -10.5 ppm.
It was interesting that the described reactions of I with the C-nucleophiles did not stop at the formation of the s-adducts but involved oxidation to the aromatic substitution products during the course of the reaction:
It is noteworthy that the described transformations of unsubstituted quinoxaline with the C-nucleophiles were simple and practically waste-free methods for producing Compound I reacted differently with 3-methyl-1-phenylmethylpyrazol-5-one in DMSO in the presence of base. Thus, the reaction of I with 3-methyl-1-phenylmethylpyrazol-5-one in DMSO in the presence of NEt 3 (TEA) produced the known dipyrazolylmethane (III) (Scheme 2) [7] and
It is noteworthy that brief heating of IV in refluxing DMF gave III. Product IV was transformed into III also in DMF solution in the presence of I 2 at room temperature. The transformation IV > III occurred also with brief heating of the crystals at 255 -260°C.
The formation mechanism of IV from I apparently included the steps of nucleophilic addition of two molecules of 1-phenyl-3-methylpyrazol-5-one to the C=N bonds of quinoxaline to form bis-adduct I 1 (Scheme 3) and cleavage of bis-adduct I 1 to form intermediate I 2 and subsequent transformation of the latter into IV.
It is noteworthy that the synthesis of III and IV that was reported earlier [8] was carried out via the reaction of unsubstituted quinoxaline with 3-methyl-1-phenylpyrazol-5-one under conditions analogous to those described in the present work. This indicated that the F atoms located in the 6-and 7-positions of I had practically no effect on this transformation.
However, the presence in the aromatic core of such labile leaving groups as F atoms opened additional opportunities for synthesizing quinoxaline derivatives.
It was found during the course of the present work that products IIa -c reacted smoothly with N-methylpiperazine at 115 -120°C in DMF solution to form the corresponding 7-methylpiperazino-derivatives of quinoxalines Va -c in 50 -60% yields (Scheme 4).
The molecular weights of compounds V as determined by mass spectrometry corresponded with those calculated. 1 H-13 C HMBC experiment (Fig. 1) . In fact, this same C atom gave a cross-peak with proton H-3 (d H = 10.09 ppm) in the 2D 1 H-13 C HMBC spectrum. This was possible only for 7-substituted methylpiperazine derivative Va.
Thus, the combined NMR results suggested that Va -c were substitution products of F-7 by N-methylpiperazine.
Because products V were the principal substitution products from the reaction with N-methylpiperazine, it could be assumed that the CH-acidic functional group in the 2-position of compounds II activated F-7 of the aromatic quinoxaline core more toward amines.
Compounds IIa and Va, which contained a dimedone moiety in the 2-position of the quinoxaline ring, could theoretically exist in several tautomeric forms (Scheme 5). The PMR and 13 C NMR spectra lacked resonances indicating the existence in these solvents of the hypothetical tautomer in which dimedone C-2¢ had sp 3 -hybridization. PMR spectra of IIa and Va in CDCl 3 solution gave a resonance for NH (or OH) as a narrow singlet that was shifted considerably to weak field (d H 18.3 and 17.4 ppm, respectively). This indicated that the molecules included a strong intramolecular H-bond (IMHB). The slight difference of the chemical shifts of dimedone C atoms C-1¢ and C-3¢ (d C = 1.8 ppm for IIa and 1.3 ppm for Va) argued in favor of tautomer K. Greater differences in the chemical shifts of the carbonyl C atoms could be expected for tautomer E. However, an analysis of 2D 1 H-13 C HMBC experiments was consistent with the presence of both tautomeric forms K and E.
In fact, on one hand we observed cross-peaks between the NH proton and C-3, C-4a, and C-2 that were characteristic of tautomer K. On the other, the HMBC spectrum of IIa showed cross-peaks between a weak-field proton and C-3¢ (194.35 ppm) and C-4¢ (48.65 ppm) that either could occur in tautomer E or could be due to transfer of spin-spin coupling through an IMHB in tautomer K. In both instances, the strongest cross-peak corresponded to coupling of the NH proton and C-2¢. However, such coupling could occur in both tautomeric forms.
We measured chemical shifts of 15 N through 2D [9] .
Considering the aforementioned, it could be assumed that tautomeric equilibrium in CHCl 3 solution was shifted toward tautomer K. However, tautomeric form E contributed noticeably to the equilibrium state.
Thus, substituents could be introduced sequentially into different parts of the quinoxaline core and new potentially biologically active derivatives could be obtained intentionally owing to the different lability of the H atoms in the heterocyclic ring and the F atoms in the aromatic fragment and the use of appropriate activation methods. Therefore, products from substitution of one of the F atoms by amines were of definite interest. These did in fact contain pharmacophores analogous to those in fluoroquinolone antibiotics [10] .
EXPERIMENTAL PART
1 H, 19 F, and 13 C NMR spectra of IIa and Va were recorded on a Bruker Avance-500 instrument. The internal standard for 1 H and 13 C NMR spectra was TMS; for 19 F NMR spectra, hexafluorobenzene. Resonances in PMR and 13 C NMR spectra for IIa and Va were assigned based on 2D Reaction of I with 3-methyl-1-phenylpyrazol-5-one in the presence of base. Compound I (0.166 g, 1.0 mmol) and 3-methyl-1-phenylpyrazol-5-one (0.522 g, 3.0 mmol) in DMSO (2 mL) were held for 48 h at room temperature in the presence of TEA (0.3 mL), diluted with H 2 O (1:1), and acidified with HCl solution (15%) until the pH was 5 -6. The resulting precipitate was filtered off, washed with hot EtOH (10 mL), and dried at 100°C to afford IV (0.340 g, 47%), mp > 250°C. The EtOH rinsings were cooled. The resulting precipitate of III was filtered off. Yield 0.025 g (7%). Compound III was identified by melting point and spectral char- 
